Drug intelligence / Profile preview

jinnakumab

Development stage: Unknown
Lead developer: Changchun GeneScience Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

Jinnakumab is a humanized monoclonal antibody targeting interleukin-1 beta (IL-1β), developed by Changchun Jinsai Pharmaceutical (GenSci). It is designed to treat autoinflammatory conditions such as systemic juvenile idiopathic arthritis (sJIA) and gouty arthritis by neutralizing IL-1β and preventing its binding to the IL-1 receptor. This inhibition blocks the pro-inflammatory cascade responsible for the systemic symptoms and joint destruction associated with these diseases. Jinnakumab is currently undergoing clinical evaluation in China to provide a targeted therapeutic option for patients with these conditions.

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on jinnakumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jinnakumab.

Explore the full profile